ACRS: Aclaris Therapeutics Growth-Adjusted Market Cap to Net Income

Risks associated with the dependence on small molecule clinical trials at Aclaris Therapeutics (ACRS) are offset by lucrative licensing agreements that strengthen capital. The current PEG ratio reflects a market valuation where the parameter has stabilized at 0.00. Business stability is further supported by scientific alliances with immunology centers to develop therapies for skin pathologies.
Metric breakdowns and analytics for Aclaris (ACRS)

Aclaris Therapeutics' development of innovative treatments for inflammatory skin and joint pathologies requires a precise alignment of R&D expenditures with future returns. An analysis of the company's price-to-growth ratio on GURU.Markets allows for an assessment of the current P/E multiple relative to projected earnings growth, where a value below one signals that the asset is undervalued and possesses high capital resilience.